{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:06:39Z","timestamp":1787169999318,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To report the incidence, cumulative mortality, and factors influencing the outcomes from a large series of COVID-19-associated mucormycosis (CAM) from western India.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Consecutive patients with CAM between March 1 and May 10, 2021, with a minimum follow-up of 1 month were included. We recorded the presence of diabetes, use of steroids, and need for non-invasive ventilation (NIV) from the case files. The features of orbital involvement, treatment administered, and outcomes, i.e., death, orbital exenteration, or recovery were noted. Cumulative probability of adverse outcomes, defined as either death or exenteration, was reported using survival analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We treated 67 cases of CAM and found an incidence of 13.6 cases per 1,000 patients post-moderate to severe COVID-19. Uncontrolled diabetes (90%) with ketoacidosis (40%) and prior systemic steroids (84%) were the strongest predispositions. The onset of CAM was 15.1 \u00b1 9.5 days (range: 6\u201342 days) after recovery from COVID-19. The cumulative probability of an adverse outcome was 38% (95% confidence intervals [CI] = 23.7\u201356.9%) on day 20. The patients who required NIV during COVID-19 were at seven times higher risk of experiencing an adverse outcome (hazard ratios [HR] = 6.92, 95% CI = 2.9\u201316.2) while those who received amphotericin\u2013 -B had a 61% lower risk (HR = 0.39, 95% CI = 0.16\u20130.97).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The current outbreak of CAM was seen predominantly in uncontrolled diabetics, especially with ketoacidosis and steroid intake. The cumulative probability of death or orbital exenteration was 38% at day 20 of the infection and those who required NIV and did not receive amphotericin-B were at a high risk of these outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1767_21","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T06:54:59Z","timestamp":1638255299000},"page":"3678-3683","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Incidence, cumulative mortality and factors affecting the outcome of COVID-19-associated mucormycosis from Western India"],"prefix":"10.4103","volume":"69","author":[{"given":"Archana Ajay","family":"Vare","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snehalata","family":"Yellambkar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Farheen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varsha","family":"Nandedkar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swati S","family":"Bhombe","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachana","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Government Medical College, Aurangabad, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,11,26]]},"reference":[{"key":"B1-20240828","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/myc.13256","article-title":"The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis","volume":"64","author":"Ahmadikia","year":"2021","journal-title":"Mycoses"},{"key":"B2-20240828","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.mmcr.2021.03.006","article-title":"Pulmonary aspergillosis and mucormycosis in a patient with COVID-19","volume":"32","author":"Johnson","year":"2021","journal-title":"Med Mycol Case Rep"},{"key":"B3-20240828","doi-asserted-by":"crossref","first-page":"746","DOI":"10.5946\/ce.2020.180","article-title":"Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report","volume":"53","author":"Monte Junior","year":"2020","journal-title":"Clin Endosc"},{"key":"B4-20240828","first-page":"1","article-title":"A challenging complication following SARS-CoV-2 infection: A case of pulmonary mucormycosis","volume":"2020","author":"Pasero","journal-title":"Infection"},{"key":"B5-20240828","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4103\/ijo.IJO_3047_20","article-title":"Post-COVID-19 opportunistic candida retinitis: A case report","volume":"69","author":"Bhagali","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B6-20240828","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.4103\/ijo.IJO_3755_20","article-title":"A case series of presumed fungal endogenous endophthalmitis in post-COVID-19 patients","volume":"69","author":"Shah","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B7-20240828","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s11046-020-00462-9","article-title":"Fungal co-infections associated with global COVID-19 pandemic: A clinical and diagnostic perspective from China","volume":"185","author":"Song","year":"2020","journal-title":"Mycopathologia"},{"key":"B8-20240828","doi-asserted-by":"crossref","first-page":"244","DOI":"10.4103\/ijo.IJO_3774_20","article-title":"Mucor in a viral land: A tale of two pathogens","volume":"69","author":"Sen","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B9-20240828","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.4103\/ijo.IJO_310_21","article-title":"Rise of the phoenix: Mucormycosis in COVID-19 times","volume":"69","author":"Ravani","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B10-20240828","doi-asserted-by":"crossref","first-page":"85","DOI":"10.14740\/jmc3637","article-title":"Rhinocerebral mucormycosis and COVID-19 pneumonia","volume":"12","author":"Alekseyev","year":"2021","journal-title":"J Med Cases"},{"key":"B11-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11046-021-00528-2","article-title":"Coronavirus disease (COVID-19) associated mucormycosis (CAM): Case report and systematic review of literature","volume":"186","author":"Garg","year":"2021","journal-title":"Mycopathologia"},{"key":"B12-20240828","doi-asserted-by":"crossref","first-page":"105957","DOI":"10.1016\/j.ijscr.2021.105957","article-title":"Sino-orbital mucormycosis in a COVID-19 patient: A case report","volume":"82","author":"Maini","year":"2021","journal-title":"Int J Surg Case Rep"},{"key":"B13-20240828","first-page":"e10726","article-title":"Rhino-orbital mucormycosis associated with COVID-19","volume":"12","author":"Mehta","year":"2020","journal-title":"Cureus"},{"key":"B14-20240828","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1097\/IOP.0000000000001889","article-title":"Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome","volume":"37","author":"Mekonnen","year":"2021","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"B15-20240828","doi-asserted-by":"crossref","first-page":"e241663","DOI":"10.1136\/bcr-2021-241663","article-title":"COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world?","volume":"14","author":"Revannavar","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B16-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12663-021-01547-8","article-title":"COVID-19 and mucormycosis of the craniofacial skeleton: Causal, contributory or coincidental?","volume":"20","author":"Verma","year":"2021","journal-title":"J Maxillofac Oral Surg"},{"key":"B17-20240828","first-page":"e13163","article-title":"A Case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19","volume":"13","author":"Waizel-Haiat","year":"2021","journal-title":"Cureus"},{"key":"B18-20240828","doi-asserted-by":"crossref","first-page":"264.e5","DOI":"10.1016\/j.ajem.2020.09.032","article-title":"Mucormycosis with orbital compartment syndrome in a patient with COVID-19","volume":"42","author":"Werthman-Ehrenreich","year":"2021","journal-title":"Am J Emerg Med"},{"key":"B19-20240828","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.4103\/ijo.IJO_1565_21","article-title":"Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), report 1","volume":"69","author":"Sen","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"B20-20240828","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/IOP.0000000000002030","article-title":"Clinical presentations, management and outcomes of rhino-orbital-cerebral mucormycosis (ROCM) following COVID-19: A multi-centric study","volume":"37","author":"Dave","year":"2021","journal-title":"Ophthalmic Plastic Reconstr Surg"},{"key":"B21-20240828","first-page":"1","article-title":"Rhino-orbital mucormycosis following COVID-19 in previously non-diabetic, immunocompetent patients","volume":"2021","author":"Nair","journal-title":"Orbit"},{"key":"B22-20240828","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.4103\/ijo.IJO_1165_21","article-title":"Code mucor: Guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19","volume":"69","author":"Honavar","year":"2021","journal-title":"Indian J Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1767_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:16:22Z","timestamp":1787166982000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1767_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,26]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1767_21","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,26]]},"assertion":[{"value":"2021-07-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}